118 F. Supp. 3d 646
D.N.J.2015Background
- Otsuka owns FDA-approved Abilify® (aripiprazole) and listed U.S. Patents Nos. 8,017,615 and 8,580,796 in the Orange Book; Torrent filed an ANDA with a Paragraph IV certification seeking to market generic aripiprazole.
- Torrent served Otsuka with a detailed notice explaining why Torrent’s ANDA does not infringe the '615 and '796 patents and produced relevant ANDA portions.
- Otsuka sued Torrent for patent infringement under the Hatch-Waxman scheme; Torrent answered and asserted counterclaims for unlawful monopolization (sham litigation under the Sherman Act) and patent misuse.
- Otsuka moved to dismiss both counterclaims under Rule 12(b)(6) and alternatively sought bifurcation and a stay; Torrent opposed, arguing it alleged sufficient facts for antitrust standing and to rebut Noerr-Pennington immunity.
- The court evaluated pleading sufficiency under Twombly/Iqbal standards, applying Third Circuit antitrust‑standing (AGC) factors and the two‑part sham litigation test from Professional Real Estate Investors.
Issues
| Issue | Plaintiff's Argument (Otsuka) | Defendant's Argument (Torrent) | Held |
|---|---|---|---|
| Antitrust standing (antitrust injury) | Torrent lacks antitrust standing because any delay was voluntary and not immediate; no cognizable antitrust injury | Litigation blocks Torrent’s ability to enter market; Otsuka’s suit is the only remaining barrier after patent expiry and FDA approval, so injury is real and immediate | Denied dismissal: Torrent pleaded plausible antitrust injury and standing at pleadings stage |
| Noerr‑Pennington immunity / sham litigation exception | Otsuka’s litigation is immune; Torrent’s allegations are conclusory and insufficient to overcome immunity | Torrent alleged detailed pre‑suit non‑infringement statement and ANDA materials, supporting that suit was objectively baseless and brought for anticompetitive purpose | Denied dismissal: Torrent’s factual allegations plausibly overcome Noerr‑Pennington at this stage; factual issues reserved for discovery |
| Patent misuse | Otsuka argues Torrent’s misuse claim is conclusory and legally deficient | Torrent claims bad‑faith suit and baseless assertions amount to misuse | Granted dismissal: Torrent failed to allege the required element that Otsuka impermissibly broadened the patent’s physical or temporal scope; dismissal without prejudice with leave to amend |
| Bifurcation and stay of antitrust counterclaim | Otsuka requested bifurcation/stay to promote efficiency and avoid prejudice | Torrent agreed to bifurcate and stay its antitrust claim | Granted: Antitrust counterclaim bifurcated and stayed pending resolution of patent infringement issues |
Key Cases Cited
- Eastern R.R. Presidents Conf. v. Noerr Motor Freight, 365 U.S. 127 (Noerr‑Pennington doctrine establishes petitioning immunity)
- United Mine Workers v. Pennington, 381 U.S. 657 (application of Noerr‑Pennington to concerted petitioning)
- Professional Real Estate Investors v. Columbia Pictures Indus., 508 U.S. 49 (two‑part sham‑litigation test)
- Associated Gen. Contractors v. California State Council of Carpenters, 459 U.S. 519 (antitrust‑standing considerations)
- Bell Atlantic v. Twombly, 550 U.S. 544 (plausibility pleading standard)
- Ashcroft v. Iqbal, 556 U.S. 662 (pleading standard and stripping conclusory allegations)
- Princo Corp. v. Int’l Trade Comm’n, 616 F.3d 1318 (patent misuse requires impermissible broadening of patent scope)
- Zenith Radio Corp. v. Hazeltine Research, 395 U.S. 100 (patent misuse doctrine described)
- Blonder‑Tongue Labs. v. Univ. of Ill. Found., 402 U.S. 313 (limitations on patent monopoly to legitimate scope)
- Broadcom Corp. v. Qualcomm Inc., 501 F.3d 297 (antitrust standing and speculative future harm analysis)